To investigate the potential of targeting the IL‐2‐STAT5 pathway for TNBC breast cancer cells, we treated MDA‐MB‐231 cells with IL‐2‐IN‐1, an IL‐2 inhibitor.[70] We found that the growth of MDA‐MB‐231 cells treated with 20 μm IL‐2‐IN‐1 was significantly inhibited (Figure 7O). Here, IL2 is linked to breast carcinoma.